ArticleBlood advances2026
Complications in patients with cancer-associated thrombosis on tinzaparin by cancer site and frailty: a pooled analysis.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- LMWH dose reduction in CAT: not so fast!Blood advances · 2026Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractCancer-associated thrombosis (CAT) is a frequent and severe complication of malignancy. Although patients undergo anticoagulation, risks of recurrent venous thromboembolism (VTE) and major bleeding (MB) remain substantial, but data are limited according to specific tumor sites and in patients with frailty. Our objective was to evaluate 6-month incidences of recurrent VTE, MB, and death in patients with CAT treated with tinzaparin, and to assess the influence of tumor site and frailty on these risks. Individual patient-level data from 1413 patients were pooled from 3 prospective cohort studies and the tinzaparin arm of a randomized controlled trial. Frailty was defined as age of ≥75 years, creatinine clearance of <50 mL/min, body weight of ≤50 kg, or Eastern Cooperative Oncology Group performance status of ≥2. Cumulative incidences were estimated using Kalbfleisch and Prentice method and plotted to illustrate the benefit-risk balance by tumor site and frailty. At 6 months, cumulative incidences of recurrent VTE and MB were 6.2% and 3.4%, respectively. Recurrent VTE incidence surpassed MB incidence in gastrointestinal, lung, genitourinary, and gynecological cancers, whereas MB risk exceeded VTE risk in breast cancer. Among patients with frailty criteria, recurrent VTE risk increased with the number of frailty factors, whereas MB remained relatively stable. In patients with CAT receiving tinzaparin, VTE recurrence, unlike bleeding risk, varies according to tumor site and patient frailty. In frail patients with CAT treated with standard full-dose tinzaparin, these findings do not support routine dose modification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.